Wellfully Ltd (WFL) - Total Liabilities

Latest as of December 2023: AU$5.20 Million AUD ≈ $3.68 Million USD

Based on the latest financial reports, Wellfully Ltd (WFL) has total liabilities worth AU$5.20 Million AUD (≈ $3.68 Million USD) as of December 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Wellfully Ltd (WFL) cash flow conversion to assess how effectively this company generates cash.

Wellfully Ltd - Total Liabilities Trend (1998–2022)

This chart illustrates how Wellfully Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Wellfully Ltd (WFL) asset resilience to evaluate the company's liquid asset resilience ratio.

Wellfully Ltd Competitors by Total Liabilities

The table below lists competitors of Wellfully Ltd ranked by their total liabilities.

Company Country Total Liabilities
Jubilee Platinum
LSE:JLP
UK GBX165.84 Million
Avation PLC
LSE:AVAP
UK GBX858.09 Million
Cake Box Holdings PLC
LSE:CBOX
UK GBX34.37 Million
Suumaya Industries Limited
NSE:SUULD
India Rs2.77 Billion

Liability Composition Analysis (1998–2022)

This chart breaks down Wellfully Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Wellfully Ltd (WFL) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.58 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -3.08 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.48 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Wellfully Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Wellfully Ltd (1998–2022)

The table below shows the annual total liabilities of Wellfully Ltd from 1998 to 2022.

Year Total Liabilities Change
2022-12-31 AU$5.20 Million
≈ $3.68 Million
+159.71%
2021-12-31 AU$2.00 Million
≈ $1.42 Million
+84.66%
2020-12-31 AU$1.08 Million
≈ $766.61K
-55.05%
2019-12-31 AU$2.41 Million
≈ $1.71 Million
+307.77%
2018-12-31 AU$591.16K
≈ $418.28K
+7.30%
2017-12-31 AU$550.93K
≈ $389.82K
+9.30%
2016-12-31 AU$504.04K
≈ $356.64K
-11.16%
2015-12-31 AU$567.33K
≈ $401.42K
+0.45%
2014-12-31 AU$564.79K
≈ $399.62K
+22.48%
2013-12-31 AU$461.12K
≈ $326.27K
+10.85%
2012-12-31 AU$415.97K
≈ $294.33K
-1.76%
2011-12-31 AU$423.41K
≈ $299.59K
-5.48%
2010-12-31 AU$447.95K
≈ $316.95K
-12.13%
2009-12-31 AU$509.77K
≈ $360.69K
-54.72%
2008-12-31 AU$1.13 Million
≈ $796.52K
+176.85%
2007-12-31 AU$406.62K
≈ $287.71K
+40.05%
2006-12-31 AU$290.34K
≈ $205.43K
+309.43%
2005-12-31 AU$70.91K
≈ $50.18K
-47.67%
2004-12-31 AU$135.50K
≈ $95.88K
+1084.06%
2003-12-31 AU$11.44K
≈ $8.10K
-99.36%
2002-12-31 AU$1.80 Million
≈ $1.27 Million
-20.74%
2001-12-31 AU$2.27 Million
≈ $1.60 Million
+9.18%
2000-12-31 AU$2.08 Million
≈ $1.47 Million
-12.22%
1999-12-31 AU$2.37 Million
≈ $1.67 Million
+93.42%
1998-12-31 AU$1.22 Million
≈ $865.35K
--

About Wellfully Ltd

AU:WFL Australia Diagnostics & Research
Market Cap
$1.05 Million
AU$1.48 Million AUD
Market Cap Rank
#30171 Global
#1788 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.00
All Time High
AU$1.65
About

Wellfully Limited, together with its subsidiaries, engages in the research and development of Dermaportation and ETP transdermal drug delivery technologies. The company operates through two segments, Dermaportation Drug Delivery Technology and Devices. It is involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT … Read more